Trevi Therapeutics, Inc. Banner Image

Trevi Therapeutics, Inc. has reached its limit for free report views

Work for Trevi Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Trevi Therapeutics, Inc.

  • Ticker TRVI
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Trevi Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in New Haven, Connecticut
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. Trevi is currently developing Haduvio for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients with Parkinson’sMore disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of Haduvio, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.
Trevi Therapeutics, Inc.

Most Recent Annual Report

MOST RECENT 2020 Form 10K

Report Locked. Trevi Therapeutics, Inc. has reached its limit for free report views.

Older/Archived Annual Reports